Elzbieta Gubala

Elzbieta Gubala

Auto-generated profile, based on publicly available information

Elzbieta Gubala

Nuclear Medicine and Endocrine Oncology Department

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
MWMalgorzata Wiench
Malgorzata Wiench
KFKrzysztof Fujarewicz
Krzysztof Fujarewicz
KSKrzysztof Simek
Krzysztof Simek
MJMichał Jarząb
Michał Jarząb
AŚAndrzej Świerniak
Andrzej Świerniak
The study looked for an optimal set of genes differentiating between papillary thyroid cancer (PTC) and normal thyroid tissue and assessed the sources of variability in gene expression profiles. The analysis was done by oligonucleotide microarrays (GeneChip HG-U133A) in 50 tissue samples taken intraoperatively from 33 patients (23 PTC patients and 10 patients with other thyroid disease). In the initial group of 16 PTC and 16 normal samples, we assessed the sources of variability in the gene expression profile by singular value decomposition which specified three major patterns of variability. The first and the most distinct mode grouped transcripts differentiating between tumor and normal tissues. Two consecutive modes contained a large proportion of immunity-related genes. To generate a multigene classifier for tumor-normal difference, we used support vector machines-based technique (recursive feature replacement). It included the following 19 genes: DPP4, GJB3, ST14, SERPINA1, LRP4, MET, EVA1, SPUVE, LGALS3, HBB, MKRN2, MRC2, IGSF1, KIAA0830, RXRG, P4HA2, CDH3, IL13RA1, and MTMR4, and correctly discriminated 17 of 18 additional PTC/normal thyroid samples and all 16 samples published in a previous microarray study. Selected novel genes (LRP4, EVA1, TMPRSS4, QPCT, and SLC34A2) were confirmed by Q-PCR.Our results prove that the gene expression signal of PTC is easily detectable even when cancer cells do not prevail over tumor stroma. We indicate and separate the confounding variability related to the immune response. Finally, we propose a potent molecular classifier able to discriminate between PTC and nonmalignant thyroid in more than 90% of investigated samples.

1 March 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MWMalgorzata Wiench
Malgorzata Wiench
ZWZ. Wygoda
Z. Wygoda
EGE. Gubala
E. Gubala
JWJ. Wloch
J. Wloch
KLKatarzyna Marta Lisowska
Katarzyna Marta Lisowska
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
PURPOSE: The study was undertaken to evaluate the frequency of inherited medullary thyroid carcinoma (MTC) among patients with apparent sporadic disease. A stepwise algorithm was used depending on clinical indices and the age of patient at MTC diagnosis. PATIENTS AND METHODS: One hundred sixteen patients with MTC verified by postoperative pathologic examination were subjected to genetic analysis of RET exons 10, 11, 13, 14, and 16 by means of polymerase chain reaction, restriction endonuclease digestion, and DNA sequencing. RESULTS: Among 116 apparent sporadic MTC patients, we identified eleven (9.5%) RET germline mutation carriers. Seven of these (6.0%) were found by routine analysis (exons 10 and 11). The frequency of inherited disease among patients younger than 45 years at diagnosis was 10.2% by analysis of typical mutations in exons 10 and 11. Extended genetic analysis (sequencing of exons 11, 13, 14, and 16) yielded 6.1% additional diagnoses, giving a risk of 16.3% in this age group. One previously unreported mutation in exon 11 affected codon 649 (TCG>TTG, Ser>Leu). In the true sporadic MTC patients younger than 30 years at diagnosis, frequencies of 36% and 4.5% in polymorphic variants L769L and S836S, respectively, were observed. The frequency for L769L was higher than in older patients (P < .05). CONCLUSION: The frequency of inherited disease among apparent sporadic medullary thyroid carcinoma patients is close to 10% in the Polish population of MTC patients. The extended analysis of all known RET proto-oncogene mutation sites is obligatory in patients younger than 45 years at diagnosis, but we also see the need to analyze the impact of rarer mutations in older patients.

10 December 2009 in Folia Histochemica et Cytobiologica
Verified
Journal Article
Open access
PDF file
MOMarek Olakowski
Marek Olakowski
TTTomasz Tyszkiewicz
Tomasz Tyszkiewicz
MJMichał Jarząb
Michał Jarząb
RKRobert Król
Robert Król
MOMalgorzata Oczko-Wojciechowska
Malgorzata Oczko-Wojciechowska
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.

1 May 2006 in Thyroid®
Verified
Journal Article
Closed access
DKDorota Kula
Dorota Kula
TBTomasz Bednarczuk
Tomasz Bednarczuk
BJBeata Jurecka-Lubieniecka
Beata Jurecka-Lubieniecka
JPJoanna Polanska
Joanna Polanska
KHKornelia Hasse-Lazar
Kornelia Hasse-Lazar
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
Objective: To study interactions between the two most widely confirmed Graves’ disease (GD) loci: HLA-DRB1 and CTLA-4. HLA-DRB1∗03 (risk allele) and DRB1∗07 (protective allele) were analyzed in this aspect, the linked TNF G(-308)A polymorphism was also considered. Design: A case-control study of 429 patients with GD compared to 308 healthy subjects. The impact of genes and their interactions were analyzed by stepwise logistic regression. Results: The independent effects of DRB1∗03 and DRB1∗07 were confirmed in our study both by stratification studies and logistic regression. CTLA-4 did not appear to be associated with GD when the interactions with other genes were considered. By logistic regression we observed a significant interaction between DRB1∗07 and CTLA-4 and revealed that CTLA-4 49G attenuated the DRB1∗07-related protection, the effect noticed also in three-way stratification studies. We confirmed that the TNF G(–308)A polymorphism is only a marker of the DRB1 status. Conclusion: Our results stress the importance of complex gene interactions in the multigene predisposition to GD. The interactions between two predisposing loci, DRB1 and CTLA-4, are exerted rather by DRB1∗07 than DRB1∗03 allele: CTLA-4 acts via switching off the protective DRB1∗07 influence, whereas the effect of DRB1∗03 is independent.

6 August 2009 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
JJJerzy Jarzab
Jerzy Jarzab
BFBarbara Filipowska
Barbara Filipowska
JZJadwiga Zebracka
Jadwiga Zebracka
MKMałgorzata Kowalska
Małgorzata Kowalska
ABAndrzej Bożek
Andrzej Bożek
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
Background: Discovery of the significant impact of filaggrin (FLG) mutations on the genetic predisposition to atopic dermatitis (AD) focused attention on the 1q21 locus, where not only FLG but also other epidermal genes are located. In the present study, we compared 1q21 gene expression in lesional versus nonlesional AD skin. Methods: A real-time quantitative PCR analysis of 10 1q21 genes, selected on the basis of a previous microarray study, was performed in skin biopsies from 33 individuals with AD. Three alternative pathway keratins were also evaluated. Results: In chronic AD skin lesions, we observed an increase in RNA encoding involucrin, S100 calcium-binding proteins A2 and A7–A9 and small proline-rich region (SPRR) proteins 1A and 2C, with fold changes ranging from 2.0 for S100A2 to 15.4 for S100A8 (p < 0.001, Bonferroni corrected), in parallel to the overexpression of the alternative pathway keratins 6A, 6B and 16. The loricrin (LOR) expression level was significantly decreased in lesional AD skin (fold change 0.5; p < 0.01). The expression of the majority of 1q21 genes and alternative keratins was closely correlated; however, for SPRR1A (and SPRR2C) in lesional skin, the correlation with other genes was lost. Conclusions: We hypothesize that the deregulated increase in SPRR1A expression in chronic atopic skin lesions reflects an insufficient rise in SPRR transcripts, unable to compensate for the lack of LOR and thus contributing to the persistence of chronic AD skin lesions. Turning off the stress response in the skin may be regarded as a goal in the treatment of AD skin lesions, and SPRR genes might be targets for such an approach.

11 September 2001 in British Journal of Cancer
Verified
Journal Article
Open access
BCB Czarnocka
B Czarnocka
DPD Pastuszko
D Pastuszko
MJM Janota-Bzowski
M Janota-Bzowski
AWA P Weetman
A P Weetman
PWP F Watson
P F Watson
DLDariusz Lange
Dariusz Lange
There is disagreement concerning the expression of thyroid peroxidase (TPO) in thyroid cancer, some studies finding qualitative as well as quantitative differences compared to normal tissue. To investigate TPO protein expression and its antigenic properties, TPO was captured from a solubilizate of thyroid microsomes by a panel of murine anti-TPO monoclonal antibodies and detected with a panel of anti-human TPO IgGκ Fab. TPO protein expression in 30 samples of malignant thyroid tissue was compared with TPO from adjacent normal tissues. Virtual absence of TPO expression was observed in 8 cases. In the remaining 22 malignant thyroid tumours the TPO protein level varied considerably from normal to nearly absent when compared to normal thyroid tissue or tissues from patients with Graves' disease (range less than 0.5 to more than 12.5 μg mg−1 of protein). When expressed TPO displayed similar epitopes, to that of TPO from Graves' disease tissue. The results obtained by the TPO capturing method were confirmed by SDS-PAGE and Western blot analysis with both microsomes and their solubilizates. The present results show that in about two-thirds of differentiated thyroid carcinomas, TPO protein is expressed, albeit to a more variable extent than normal; when present, TPO in malignant tissues is immunologically normal. © 2001 Cancer Research Campaignhttp://www.bjcancer.com